Evidence map›Paper›PMID 29971677›Full record

ArticleAnnals of surgical oncology2018

Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.

Koji Matsuo, Yutaka Takazawa, Malcolm S Ross, Esther Elishaev, Mayu Yunokawa, Todd B Sheridan, Stephen H Bush, Merieme M Klobocista, Erin A Blake, Tadao Takano and 40 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. A Single-Cell Atlas of Uterine Carcinosarcoma from Diverse Ancestries.bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Article
  4. Uterine carcinosarcoma: Unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 2 countries.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. koji.matsuo@med.usc.edu.
Yutaka TakazawaDepartment of Pathology, Cancer Institute Hospital, Tokyo, Japan.
Malcolm S RossDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, MaGee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, USA.
Esther ElishaevDepartment of Pathology, MaGee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, USA.
Mayu YunokawaDepartment of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Todd B SheridanDepartment of Pathology, Mercy Medical Center, Baltimore, MD, USA.
Stephen H BushDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
Merieme M KlobocistaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA.
Erin A BlakeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, Boulder, CO, USA.
Tadao TakanoDepartment of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan.
Tsukasa BabaDepartment of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
Shinya SatohDepartment of Obstetrics and Gynecology, Tottori University, Tottori, Japan.
Masako ShidaDepartment of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan.
Yuji IkedaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Sosuke AdachiDepartment of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
Takuhei YokoyamaDepartment of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka, Japan.
Munetaka TakekumaDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Shiori YanaiDepartment of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan.
Satoshi TakeuchiDepartment of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
Masato NishimuraDepartment of Obstetrics and Gynecology, Tokushima University, Tokushima, Japan.
Keita IwasakiDepartment of Obstetrics and Gynecology, Aichi Medical University, Aichi, Japan.
Marian S JohnsonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Medical Center, Lexington, KY, USA.
Masayuki YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Ardeshir HakamDepartment of Pathology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
Hiroko MachidaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
Paulette Mhawech-FaucegliaDepartment of Pathology, University of Southern California, Los Angeles, CA, USA.
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Kiyoshi YoshinoDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Hiroshi KajiwaraDepartment of Pathology, Tokai University, Kanagawa, Japan.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Masanori YasudaDepartment of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.
Takahito M MiyakeDepartment of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.
Takuya MoriyaDepartment of Pathology, Kawasaki Medical School, Okayama, Japan.
Yoshiaki YubaDepartment of Pathology, Kitano Hospital, Osaka, Japan.
Terry MorganDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
Tomoyuki FukagawaDepartment of Pathology, Iwate Medical University, Morioka, Japan.
Tanja PejovicDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA.
Tadayoshi NaganoDepartment of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.
Takeshi SasakiDepartment of Pathology, The University of Tokyo, Tokyo, Japan.
Abby M RichmondDepartment of Pathology, University of Colorado, Boulder, CO, USA.
Miriam D PostDepartment of Pathology, University of Colorado, Boulder, CO, USA.
Mian M K ShahzadDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
Dwight D ImDepartment of Gynecology, Mercy Medical Center, Baltimore, MD, USA.
Hiroshi YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
Kohei OmatsuDepartment of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Frederick R UelandDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Medical Center, Lexington, KY, USA.
Joseph L KelleyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, MaGee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, USA.
Rouzan G KarabakhtsianDepartment of Pathology, University of Kentucky Medical Center, Lexington, KY, USA.
Lynda D RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
University of Southern California · USUniversity of Colorado Boulder · USUniversity of Pittsburgh · USUniversity of South Florida · USAlbert Einstein College of Medicine · USIwate Medical University · JPKawasaki Medical School · JPKitano Hospital · JPMercy Medical Center · USNiigata University · JPOregon Health & Science University · USThe Cancer Institute Hospital · JPThe University of Osaka · JPThe University of Tokyo · JPTokai University · JPTokyo National Hospital · JPUniversity of Kentucky · USAichi Medical University · JPKurashiki Medical Center · JPKyoto University · JP

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectiveThe aim of this study was to examine the significance of lymphovascular space invasion (LVSI) with a sarcomatous component on the tumor characteristics and clinical outcomes of women with uterine carcinosarcoma (UCS).

methodsThis was a secondary analysis of a prior multicenter retrospective study that examined women with stage I-IV UCS who underwent primary hysterectomy. Archived histopathology slides were reviewed and LVSI was scored as follows: LVSI with a carcinomatous component alone (LVSI-carcinoma; n = 375, 76.8%) or LVSI containing a sarcomatous component with or without a carcinomatous component (LVSI-sarcoma; n = 113, 23.2%). Qualitative metrics of LVSI were correlated to clinicopathological factors and survival outcome.

resultsTumors in the LVSI-sarcoma group were more likely to have sarcoma dominance (82.1 vs. 26.4%) heterologous sarcomatous component (51.3 vs. 37.9%), low-grade carcinoma (42.5 vs. 22.4%), and large tumor size (81.0 vs. 70.2%) in the primary tumor site compared with tumors in the LVSI-carcinoma group (all p < 0.05). On multivariate analysis, LVSI-sarcoma was independently associated with decreased progression-free survival (5-year rates: 34.9 vs. 40.8%, adjusted hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.36-2.50, p < 0.001), and cause-specific survival (5-year rates: 41.8 vs. 55.9%, adjusted HR 1.95, 95% CI 1.39-2.75, p < 0.001) compared with LVSI-carcinoma. Postoperative radiotherapy for women with LVSI-sarcoma had a higher reduction rate of recurrence/progression of disease (54% reduction, p = 0.04) compared with postoperative radiotherapy for women with LVSI-carcinoma (26% reduction, p = 0.08).

conclusionIn UCS, the presence of a sarcomatous component in LVSI is particularly prevalent when a tumor has sarcoma dominance. Our study suggests that LVSI containing a sarcomatous component may be a predictor of decreased survival for women with UCS.

Indexed as

Blood VesselsCarcinosarcomaChemotherapy, AdjuvantDisease ProgressionFemaleHumansHysterectomyLymphatic MetastasisLymphatic VesselsMiddle AgedNeoplasm InvasivenessProgression-Free SurvivalRadiotherapy, AdjuvantRetrospective StudiesSurvival RateUterine Neoplasms

Identifiers

PMID29971677
PMCPMC7523233
OpenAlexW2811435260

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.